New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
New data from a phase 2b study being presented at the 2026 annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), show that, for people living with obesity and type 2 diabetes, treatment with Eli Lilly's new investigational medication, EloraTZP, a combination of eloralintide and tirzepatide (TZP), resulted in weight loss of up to 23.3% at…
New study data presented at the 2026 EASD annual meeting reveals that a combination of Eli Lilly's experimental drugs eloralintide and tirzepatide (TZP) can lead to significant weight loss and improved blood sugar control in patients with obesity and type 2 diabetes. The 48-week trial involving 367 adults found that the highest dose (Elora 9 mg + TZP 15 mg) resulted in an average 23.3% body weight reduction (24.6 kg or 54.2 pounds) and a 2.9% decrease in HbA1c levels.
The most frequent side effects were mild gastrointestinal issues that occurred more often during combination therapy than with either drug alone.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
